Biomaterials 278 , 121169 (2021)
Researchers from the Case Western Reserve University School of Medicine in Cleveland, Ohio, looked at three years of electronic medical records of almost over 1 million patients with type 2 diabetes, including those prescribed semaglutide, who had never been diagnosed with Alzheimer's disease and had at least one other cardiometabolic risk factor such as obesity, high blood pressure, elevated cholesterol, chronic kidney disease or history of stroke
At enrollment, all participants signed the informed consent
Patient Safety and Risk Mitigation: PA acts as a safeguard, prompting prescribers to consider contraindications, drug interactions, and patient-specific factors (e.g., history of medullary thyroid carcinoma) that might make GLP-1 use unsuitable, thereby reducing adverse events